Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51 on Long Term Immunogenicity. An Uncontrolled, Open-label Phase 3 Study.

NCT00595309 is registered in ClinicalTrials.gov with Valneva Austria GmbH as lead sponsor.

NCT NCT00595309
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00595309 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51 on Long Term Immunogenicity. An Uncontrolled, Open-label Phase 3 Study.
Lead sponsor
Valneva Austria GmbH
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2007
Completion date
October 31, 2009
Enrollment
198 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

japanese encephalitis